Clinical trial · Interventional
Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol
NCT03245554CI-TRIAL-00032429unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To research the effect of propranolol on the proliferation and apoptosis of gastrointestinal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Propranolol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- placebo and propranolol
- description
- We used propranolol and placebo as an control drug to treat with patients.
- interventionNames
- Drug: Propranolol
Primary outcomes (1)
- measure
- Tumor size will be measured.
- timeFrame
- Our experiment completed after patients took medicine for one week.
- description
- We used CT and Ki67 to confirm that the drug's affection.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. patients with gastric adenocarcinoma and colon cancer were diagnosed by histology and cytology, and there was a clear metastasis (TxNxM0); 2. without any prior treatment (including surgery or radiotherapy and chemotherapy) in the I-III period, no distant metastasis, suitable for patients with surgical resection of the tumor. 3. the age range of the patients is 18-60; 4. systolic pressure 100-140mmHg; heart rate \>60bpm; 5. the patient's survival time should be longer than 3 months; 6. without previous cardiovascular and cerebrovascular diseases, the atrioventricular block was excluded by the 24 hour dynamic electrocardiogram; 7. ECOG score of 2 (that means the patient's bed time is less than 50%); Karnofsky score of 60% (that means patients have the basic activities and self-care ability); 8. the basic biochemical examination results of patients with normal: white blood cell 3000/ul; neutrophil 1500/ul 100000/ul; platelet count; total bilirubin \< 1.5 x ULN; AST / ALT 2.5 x ULN without liver metastasis; \< 5 x ULN liver metastasis; creatinine clearance rate of 1.5 x ULN; 9. have the ability to understand and sign informed consent. Exclusion Criteria: 1. pregnant or lactating women; 2. patients with severe heart disease, kidney disease, metabolic disorders, bronchial asthma, cardiogenic shock, heart block (II-III degree atrioventricular block), or severe acute heart failure, sinus bradycardia. 3. patients with epilepsy or psychotropic drugs and sedatives; 4. patients with brain metastasis and bone marrow metastasis; 5. participants in clinical trials of other drugs within 4 weeks; 6. patients with a history of anaphylaxis with propranolol; 7. patients treated with trastuzumab; 8. patients with or reactive immunodeficiency, such as those with HIV infection; 9. the uncontrollable situation in the group during the period (but not limited to these cases): according to the experimental scheme of medication, severe infection, due to mental illness or other social factors lead to the compliance requirements of patients; 10. patients with atrioventricular block should be discontinued immediately and quit; 11. the researchers believe there may be any increase in the risk of the subject or any interference with clinical trials.
References
Publications (0)
Data not yet available
No reference posted for this study.